PSI and Apollo Health Ventures have launched Focal Biosciences. The newly established biotech company aims to redefine the treatment of age-related diseases by reprogramming deregulated processes in cells that cause the detrimental processes underlying many serious diseases of aging that represent a significant health burden. The newly founded entity will initially operate out of the Paul Scherrer Institute.
We wish Focal Biosciences every success for the further development of the company.
https://www.psi.ch/en/media/our-research/paul-scherrer-institute-and-ap…
https://www.admin.ch/gov/en/start/documentation/media-releases.msg-id-9…
G.V. Shivashankar is head of the Laboratory of Nanoscale Biology at Paul Scherrer Institute, Professor of Mechano-Genomics, ETH Zurich and a recognized leader in mechanogenomics with strong expertise in cellular reprogramming.